Stock Track | Junshi Bio Soars 5.01% Intraday on Anticipation of AACR Clinical Data for JS207 and JS212

Stock Track

Apr 17

Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.

The surge appears driven by expectations surrounding the company's upcoming presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting. According to analyst notes, Junshi Bio is scheduled to disclose clinical data for JS207 (PD-1/VEGF) in first-line colorectal cancer and hepatocellular carcinoma, with potential entry into key registration trials this year. Additionally, early-stage data for JS212 (EGFR/HER3 ADC) will be presented, with pivotal registration trials planned to start by year-end.

Investors are positioning ahead of the data releases, betting on positive outcomes that could accelerate the drug candidates' development pathways and enhance the company's oncology portfolio value.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1197879920"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197879920\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197879920?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 13:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197879920","market":"sg","top_or_hot":-1,"title":"Stock Track | Junshi Bio Soars 5.01% Intraday on Anticipation of AACR Clinical Data for JS207 and JS212","media":"Stock Track","content":"<p>Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.</p><p>The surge appears driven by expectations surrounding the company's upcoming presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting. According to analyst notes, Junshi Bio is scheduled to disclose clinical data for JS207 (PD-1/VEGF) in first-line colorectal cancer and hepatocellular carcinoma, with potential entry into key registration trials this year. Additionally, early-stage data for JS212 (EGFR/HER3 ADC) will be presented, with pivotal registration trials planned to start by year-end.</p><p>Investors are positioning ahead of the data releases, betting on positive outcomes that could accelerate the drug candidates' development pathways and enhance the company's oncology portfolio value.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Junshi Bio Soars 5.01% Intraday on Anticipation of AACR Clinical Data for JS207 and JS212</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Junshi Bio Soars 5.01% Intraday on Anticipation of AACR Clinical Data for JS207 and JS212\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-17 13:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.</p><p>The surge appears driven by expectations surrounding the company's upcoming presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting. According to analyst notes, Junshi Bio is scheduled to disclose clinical data for JS207 (PD-1/VEGF) in first-line colorectal cancer and hepatocellular carcinoma, with potential entry into key registration trials this year. Additionally, early-stage data for JS212 (EGFR/HER3 ADC) will be presented, with pivotal registration trials planned to start by year-end.</p><p>Investors are positioning ahead of the data releases, betting on positive outcomes that could accelerate the drug candidates' development pathways and enhance the company's oncology portfolio value.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君实生物","start_time":0,"source_url":"","article_id":"1197879920","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197879920","pubTimestamp":1776404469,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.The surge appears driven by expectations surrounding the company's upcoming...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物"},"translate_title":"个股赛道|君实生物盘中暴涨5.01%，JS207、JS212获AACR临床数据预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1},"content_text":"Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.The surge appears driven by expectations surrounding the company's upcoming presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting. According to analyst notes, Junshi Bio is scheduled to disclose clinical data for JS207 (PD-1/VEGF) in first-line colorectal cancer and hepatocellular carcinoma, with potential entry into key registration trials this year. Additionally, early-stage data for JS212 (EGFR/HER3 ADC) will be presented, with pivotal registration trials planned to start by year-end.Investors are positioning ahead of the data releases, betting on positive outcomes that could accelerate the drug candidates' development pathways and enhance the company's oncology portfolio value.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}